Table of Contents Table of Contents
Previous Page  508 / 812 Next Page
Information
Show Menu
Previous Page 508 / 812 Next Page
Page Background

S504

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

Conclusion

Augmentation strategy is often used in patients with

MDD. There is no significant difference in the use combination ther-

apy based on gender and age.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1469

EV485

The Mini-Spadin, an efficient alternate

to Spadin in the depression treatment

M. Borsotto

, A. D

jillani , C. Devader , C. Heurteaux , J. Mazella

IPMC, UMR7275, Valbonne, France

Corresponding author.

Objectives

We previously discovered spadin as a newantidepres-

sant drug concept. Spadin exerts its antidepressant actions on the

TREK-1 potassium channel, a new antidepressant (AD) target. We

have shown that spadin acts more rapidly in comparison to other

ADs. We have pointed out that spadin induced neurogenesis after

only 4-day treatments. We have demonstrated that spadin did not

display side effects at the cardiac level and on TREK-1 controlled

functions such as stroke, epilepsy or pain.

Objectives

With the final goal to make spadin a drug for human

clinic, our objective was to find analogs of spadin demonstrating a

better affinity or a better in vivo stability or both.

Methods

Several analogs of spadin were synthesized. Their abil-

ity to block the TREK-1 channel activity were first tested by

electrophysiology on HEK293 cells stably transfected with TREK-1

channels. AD effects were measured by using the forced swim test

and the novelty suppressed feeding test. Neurogenesis was inves-

tigated by measuring the expression level of the synaptic protein

PSD-95 in in vitro cultured neurons.

Results

Our data allow us to identify a shortened spadin, called

mini-spadin, that displayed the same AD properties as spadin and a

400 fold increase in the TREK-1 affinity. Mini-spadin increased the

synaptogenesis marker PSD95 levels after only 24 hours of treat-

ment, suggesting that like spadin, mini-spadin was able to induce

neurogenesis and synaptogenesis.

Conclusions

Even if further experiments are required, the mini-

spadin appears to be more efficient than spadin offering a very

promising alternate to spadin as human drug.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1470

EV486

Short-term study in patients treated

with desvenlafaxine

M.P. Calvo Rivera

1 ,

, L. Aguado Bailón

1

, B. Girela Serrano

2

1

San Cecilio University Hospital, Psychiatry Service, Granada, Spain

2

Santa Ana Hospital, Psychiatry Service, Motril-Granada, Spain

Corresponding author.

Introduction

Desvenlafaxine is an antidepressant inhibitor of the

reuptake of norepinephrine and serotonin (SNRI). Several publica-

tions support its efficacy in reducing depressive symptoms in the

short term.

Objectives

The objective of this paper is to estimate the effect of

short-term (12 weeks) of patients with depressive disorder treated

with desvenlafaxine.

Methodology

This is a prospective observational study track-

ing a cohort of outpatients with depressive disorder treated with

Desvenlafaxine for three months. To accomplish our goal we used

the Montgomery-Asberg scale performing three measurements

(baseline, one month and two months after initiate the treatment).

The size of our sample was 24 patients.

Results

We found that in about 80% of patients the treatment

was effective, no significant differences in relation to sex, age or

treatment dose were reported. Regarding the severity of the symp-

toms, in the initial assessment 16% of the patients had a mild

depressive episode, 70% a moderate episode and about 12% had a

severe episode; while in the last evaluation, almost 46% of patients

were in recovery, nearly 42% had mild symptoms, 8% moderate

symptoms and only 4% had mild symptoms.

Conclusion

We can conclude that the treatment with Desven-

lafaxine has been effective at improving in the short-term the

depressive disorder, independently of gender, age and dose admin-

istered.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1471

EV487

Depression and ischemic heart

disease: The role of the endogenous

stress response system

V. Caivano

1

, F. Monteleone

1

, R. Farina

2

, D. Nunziata

1

,

G. Cascino

1 ,

, A. De Rosa

1

, G. D’Agostino

1

, L. Steardo

3

,

F. Piscione

1

, P. Monteleone

1

1

University of Salerno, Department of Medicine and Surgery, Salerno,

Italy

2

AOU “San Giovanni di Dio e Ruggi D’Aragona”, UTIC, Salerno, Italy

3

University of Naples SUN, Department of Psychiatry, Napoli, Italy

Corresponding author.

Introduction

Depression increases the risk of ischemic heart dis-

ease in healthy people and impairs the outcome of heart diseases.

The endogenous stress response system, including the autonomous

nervous system and the hypothalamus-pituitary-adrenal (HPA)

axis, seems to play a primary role in the connection between

depression and ischemic heart disease.

Objectives and aims

We investigated concomitantly the HPA axis

and the sympathetic nervous system (SNS) activities in patients

withan acute coronary syndrome (ACS), in relation to the presence

of concomitant or ongoing depression.

Methods

Fifty men and women consecutively admitted to the

inpatient cardiologic unit of the Department of Medicine of the

University of Salerno with a diagnosis of ACS underwent saliva

sample collection at awakening and 15, 30 and 60min after awak-

ening within the 7th day of their ACS attack. They were screened

for comorbid depression at admission and after 1, 3 and 6 months

after their ischemic event. Saliva cortisol and alpha-amylase levels

were measured.

Results

Major depression was diagnosed in 10% of the patients.

As a group, they exhibited a cortisol awakening response (CAR)

significantly enhanced as compared to subjectswithout depression.

Alpha-amylase levels did not differ significantly between the two

groups.

Discussion

Present findings suggest that an increase of HPA axis

activity, as measured by CAR, in the first days after an ischemic

cardiac event is associated with the risk of major depression. The

extent to which this may predict also the cardiac outcome is cur-

rently under evaluation.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1472

EV488

Facing depression with botulinum

toxin: Literature review

M. Cátia Alves

, G. Sobreira , M.A. Aleixo , J.M. Oliveira

Centro Hospitalar Psiquiátrico de Lisboa, Psychiatry, Lisbon, Portugal

Corresponding author.

Introduction

Affecting over 120 million people, major depressive

disorder (MDD) is characterized by low mood, lack of interest and